NCT00865696View on ClinicalTrials.gov

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

September 30, 2001

Study Completion Date

September 30, 2001

Conditions
Healthy
Interventions
DRUG

Mirtazapine 15 mg tablets, single dose

A: Experimental Subjects received Purepac formulated products under fasting conditions

DRUG

REMERON® 15 mg tablets, single dose

B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY